Fri, Aug 29, 2014, 12:29 AM EDT - U.S. Markets open in 9 hrs 1 mins

Recent

% | $
Quotes you view appear here for quick access.

Cytokinetics, Incorporated Message Board

aggiebioengineer 12 posts  |  Last Activity: Aug 22, 2014 7:37 PM Member since: Oct 3, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • aggiebioengineer aggiebioengineer Aug 22, 2014 7:37 PM Flag

    Hello Cars, I see you changed your ID. I could tell by your writing styles.

    What part of my text did you not understand? MM is the only one's who can afford to trade large blocks of 100 shares because they don't have to pay all that brokerage commissions you and I have to pay.

    So you want us retail traders to pay all that commissions and losses at 10c increments in hopes that MM won't drive it down, so that you can exit to minimize your losses? Talk about a scoundrel.

  • what's your agenda Cars? You are flooding this MB with non-sense. I'm not sure if you don't know what is going on or if you are deliberately lying.

    Do you honestly believe retail investors will commit large amounts of trades for 100 shares at a time and pay all that commissions?

    MM is in control right now. They are artificially running up the PPS with 100 share trades to attract buyers, then they take them down hard.

    Learn to trade.

  • Reply to

    $210B market for Obesity Implants

    by aggiebioengineer Jun 20, 2014 2:29 PM
    aggiebioengineer aggiebioengineer Jun 20, 2014 2:30 PM Flag

    Final Decision

    EnteroMedics Inc (NASDAQ:ETRM) expects the final decision on the Premarket Approval (PMA) of the market to come later this year. The device, which works through a technology known as neuro blocking, would be an important addition to the obesity treatment market, especially considering that obesity begets medical problems such as cancer, hypertension and diabetes.

  • aggiebioengineer by aggiebioengineer Jun 20, 2014 2:29 PM Flag

    EnteroMedics Inc (NASDAQ:ETRM) Pursues $210 Billion Market With Obesity Implant
    Posted on Jun 20 2014 - 11:15am by Brendan Byrne

    Boston, MA 06/20/2014 (wallstreetpr) – EnteroMedics Inc (NASDAQ:ETRM) is developing a device implant to control obesity in adults with refractory conditions. The device helps the obese by controlling appetite and digestion. The development of the device received a major boost this week when an advisory panel of the Food and Drug Administration (FDA) voted favorably on its safety and potential.

    In the U.S., obesity is almost hitting epidemic proportions because more than one third of the country’s population are said to be obese. According to a lobby group called Trust for America’s Health, obesity costs the U.S. healthcare up to $210 billion annually, based on 2012 findings.

    The widespread obese conditions in the U.S. has even become a serious concern for the U.S. policymakers and regulators, who have to encourage innovative ways to deal with the situation while also ensuring that patients are only exposed to the best obesity treatment or remedy.

    EnteroMedics Inc (NASDAQ:ETRM) is developing a device dubbed Maestro Rechargeable System (MRS), which helps to control appetite and stomach activities.

    FDA Review Of ETRM Implant

    In a vote, the FDA panel voted eight to one to recommend the device as safe. As to whether the benefits of the device outweigh its risks, the panel voted six to two in its favor, in a vote that saw one member abstain. On the efficacy side, MRS suffered a blow as only four out of five members supported it on that front. However, overall, the vote was deemed positive.

    The FDA usually follows the recommendations of its independent committees, however, and it is not compelled to do so. If the device wins approval of the regulator, it will become the first obesity targeted implant in more than a decade in the U.S.

  • Reply to

    PDUFA announcement order

    by aggiebioengineer Jun 13, 2014 12:20 PM
    aggiebioengineer aggiebioengineer Jun 13, 2014 12:31 PM Flag

    Science is half the company, management is the other half.
    I like their science, but the management can't seem to capitalize on it.

  • aggiebioengineer by aggiebioengineer Jun 13, 2014 12:20 PM Flag

    Long a go, I thought I read somewhere that FDA approval/disapproval notices are sent to the company, then give them something like 72 hours to announce it first before FDA announces it.

    Please correct me if I'm wrong...

    So, if the above is true, either FDA made a mistake by posting the announcement too soon, or NAVB mgmt had known about this already.

    Why is NAVB keeping so low profile? Incompetent management?
    Now, I'm extremely curious of what mgmt would say in their PR.

  • Reply to

    FDA Approved!!

    by aggiebioengineer Jun 13, 2014 10:31 AM
    aggiebioengineer aggiebioengineer Jun 13, 2014 12:00 PM Flag

    Your wisdom is well outspoken...
    Didn't know they had Internet Cafe in Juvenile Detention Center...

  • Reply to

    FDA Approved!!

    by aggiebioengineer Jun 13, 2014 10:31 AM
    aggiebioengineer aggiebioengineer Jun 13, 2014 11:44 AM Flag

    Yes, news is out, however, co PR has not come out yet. The PR could contain important information. They have not been successful in marketing in the past, so perhaps, they have been working on partnership or selling, who know.... I'm waiting for the PR, like many others...

  • Reply to

    FDA Approved!!

    by aggiebioengineer Jun 13, 2014 10:31 AM
    aggiebioengineer aggiebioengineer Jun 13, 2014 10:49 AM Flag

    Alright, lets see what mgmt has to say on their PR. I'll choke on air if PR says the co is being sold for $10 per share and yet the PPS drops by 50%...

  • aggiebioengineer by aggiebioengineer Jun 13, 2014 10:31 AM Flag

    News out at FDA site...

  • aggiebioengineer aggiebioengineer Jun 12, 2014 10:57 AM Flag

    Although, efficacy isn't all that great, but it still works and the device is much safer than others. Perhaps, this is what they're counting on?

  • aggiebioengineer aggiebioengineer Jun 2, 2014 1:48 PM Flag

    Even if this was $10 stock, why would anyone pay you $4 when you can get it for less in the market? Apparently, you're a bit out of touch.

    In case you're interested in knowing, I did sell 100x Nov Covered $5 Calls. Someone thinks ATRS is worth at least $5.30. Either they are stupid or knows something. Your call.

CYTK
4.31-0.10(-2.27%)Aug 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.